De novo use of a generic formulation of tacrolimus versus reference tacrolimus in kidney transplantation: evaluation of the clinical results, histology in protocol biopsies, and immunological monitoring

No abstract is available for this paper.

• Publication year

  2015

• Venue

  Transplant International

• Publication date

  2015-11-01

• Fields of study

  Medicine

• Identifiers
  DOI 10.1111/tri.12626PMID 26088437
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• An observational multi-cohort study on the use and safety of Combivir scored tablets among HIV-infected children and adolescents. Report to the European Medicines Agency (EMA)/ Committee for Medicinal Products for Human Use (CHMP)

  2014cited by this paper
• De Novo Donor-Specific Human Leukocyte Antigen Antibodies Early After Kidney Transplantation

  2014cited by this paper
• Equivalence and interchangeability of narrow therapeutic index drugs in organ transplantation

  2013cited by this paper
• Tacrolimus in transplant rejection

  2013cited by this paper
• Methods, strengths, weaknesses, and limitations of bioequivalence tests with special regard to immunosuppressive drugs

  2013cited by this paper
• Immunosuppression, Generic Drugs and the FDA

  2012cited by this paper
• Evaluation of Clinical and Safety Outcomes Associated with Conversion from Brand‐Name to Generic Tacrolimus in Transplant Recipients Enrolled in an Integrated Health Care System

  2012cited by this paper
• A Randomized Pharmacokinetic Study of Generic Tacrolimus Versus Reference Tacrolimus in Kidney Transplant Recipients

  2012cited by this paper
• A single-centre comparison of the clinical outcomes at 6 months of renal transplant recipients administered Adoport® or Prograf® preparations of tacrolimus

  2012cited by this paper
• Response to Klintmalm on the Use of Generic Immunosuppression

  2012cited by this paper
• Immunosuppression, Generic Drugs and the FDA

  2011cited by this paper
• The Impact of Conversion From Prograf to Generic Tacrolimus in Liver and Kidney Transplant Recipients With Stable Graft Function

  2011cited by this paper
• A Multicenter Experience With Generic Tacrolimus Conversion

  2011cited by this paper
• European Society for Organ Transplantation Advisory Committee Recommendations on Generic Substitution of Immunosuppressive Drugs

  2011influential reference
• KDIGO clinical practice guideline for the care of kidney transplant recipients: a summary.

  2010cited by this paper
• KDIGO clinical practice guideline for the care of kidney transplant recipients.

  2009cited by this paper
• Reduced exposure to calcineurin inhibitors in renal transplantation.

  2008cited by this paper
• Banff 07 Classification of Renal Allograft Pathology: Updates and Future Directions

  2008cited by this paper
• Banff 07 Classification of Renal Allograft Pathology : Updates and Future Directions

  2008cited by this paper
• Reduced exposure to calcineurin inhibitors in renal transplantation.

  2007cited by this paper
• Four‐year Follow‐up of a Prospective Trial of HLA and MICA Antibodies on Kidney Graft Survival

  2007cited by this paper
• The ongoing regulation of generic drugs.

  2007cited by this paper
• Tacrolimus versus cyclosporin as primary immunosuppression for kidney transplant recipients.

  2005cited by this paper
• The Banff 97 working classification of renal allograft pathology.

  1999cited by this paper
• FK-506, a novel immunosuppressant isolated from a Streptomyces. II. Immunosuppressive effect of FK-506 in vitro.

  1987cited by this paper
• FK-506, a novel immunosuppressant isolated from a Streptomyces. I. Fermentation, isolation, and physico-chemical and biological characteristics.

  1987cited by this paper

• De-novo use of generic tacrolimus (Adoport) in renal transplant recipients: A single center experience from Türkiye

  2024cites this paper
• Providing “Free” Access to Dialysis and Transplant to the Disfranchised. A Sustainable Model for Low and Low Middle Income Countries (LMICs)

  2023cites this paper
• Seeking Standardized Definitions for HLA-incompatible Kidney Transplants: A Systematic Review

  2022cites this paper
• Renal Transplantation EAU Guidelines on

  2021cites this paper
• Immunosuppression with generic tacrolimus in liver and kidney transplantation—systematic review and meta‐analysis on biopsy‐proven acute rejection and bioequivalence

  2020cites this paper
• Clinical and safety outcomes of conversion original tacrolimus to generic tacrolimus in Turkish kidney transplant recipients

  2020influential citation
• Changes in the commercial brand of tacrolimus lead to subtherapeutic trough levels and acute rejection in renal transplant recipients

  2019cites this paper
• Evaluation of Clinical and Safety Outcomes Following Uncontrolled Tacrolimus Conversion in Adult Transplant Recipients

  2019cites this paper
• Personalized immunosuppression in elderly renal transplant recipients

  2018cites this paper
• The BC Glomerulonephritis Network: Improving Access and Reducing the Cost of Immunosuppressive Treatments for Glomerular Diseases

  2018cites this paper
• A 1-year Comparison of Generic Tacrolimus (Tacniî) and Prografî in Renal Transplant Patients: A Retrospective Matched Group Analysis

  2017cites this paper
• Pharmacokinetics and Clinical Outcomes of Generic Tacrolimus (Hexal) Versus Branded Tacrolimus in De Novo Kidney Transplant Patients: A Multicenter, Randomized Trial

  2017cites this paper
• New formulations of tacrolimus and prevention of acute and chronic rejections in adult kidney-transplant recipients

  2017cites this paper
• Generic Drugs – Decreasing Costs and Room for Increased Number of Kidney Transplantations

  2015cites this paper